These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 17157627)
21. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Hauth EA; Antoch G; Stattaus J; Kuehl H; Veit P; Bockisch A; Kimmig R; Forsting M Eur J Radiol; 2005 Nov; 56(2):263-8. PubMed ID: 16233894 [TBL] [Abstract][Full Text] [Related]
22. The impact of PET/CT in the management of recurrent ovarian cancer. Simcock B; Neesham D; Quinn M; Drummond E; Milner A; Hicks RJ Gynecol Oncol; 2006 Oct; 103(1):271-6. PubMed ID: 16626793 [TBL] [Abstract][Full Text] [Related]
23. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Manegold-Brauer G; Bellin AK; Tercanli S; Lapaire O; Heinzelmann-Schwarz V Arch Gynecol Obstet; 2014 Mar; 289(3):491-8. PubMed ID: 24253338 [TBL] [Abstract][Full Text] [Related]
24. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer. Barranger E; Kerrou K; Petegnief Y; David-Montefiore E; Cortez A; Daraï E Gynecol Oncol; 2005 Jan; 96(1):241-4. PubMed ID: 15589609 [TBL] [Abstract][Full Text] [Related]
25. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. Kurtz AB; Tsimikas JV; Tempany CM; Hamper UM; Arger PH; Bree RL; Wechsler RJ; Francis IR; Kuhlman JE; Siegelman ES; Mitchell DG; Silverman SG; Brown DL; Sheth S; Coleman BG; Ellis JH; Kurman RJ; Caudry DJ; McNeil BJ Radiology; 1999 Jul; 212(1):19-27. PubMed ID: 10405715 [TBL] [Abstract][Full Text] [Related]
26. [ULTRASOUND CRITERIA OR THE OPERABILITY AND EFFICACY OF THE TREATMENT OF THE MALIGNANT EPITHELIAL OVARIAN TUMOURS]. Shkarbun KD; Shkarbun LI Lik Sprava; 2015; (7-8):105-9. PubMed ID: 27491160 [TBL] [Abstract][Full Text] [Related]
27. Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2. Alt CD; Brocker KA; Eichbaum M; Sohn C; Arnegger FU; Kauczor HU; Hallscheidt P Strahlenther Onkol; 2011 Nov; 187(11):705-14. PubMed ID: 22037656 [TBL] [Abstract][Full Text] [Related]
28. [A retrospective study of ovarian cancer with a median follow of 42 months]. Raherinantenaina F; Rakotomena SD; Hasiniatsy NR; Rakototiana FA; Rafaramino F; Ratsimba HN Pan Afr Med J; 2015; 20():211. PubMed ID: 26113942 [TBL] [Abstract][Full Text] [Related]
29. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Thrall MM; DeLoia JA; Gallion H; Avril N Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284 [TBL] [Abstract][Full Text] [Related]
30. Radiological staging of ovarian carcinoma. Moyle P; Addley HC; Sala E Semin Ultrasound CT MR; 2010 Oct; 31(5):388-98. PubMed ID: 20974358 [TBL] [Abstract][Full Text] [Related]
31. Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. Tempany CM; Zou KH; Silverman SG; Brown DL; Kurtz AB; McNeil BJ Radiology; 2000 Jun; 215(3):761-7. PubMed ID: 10831697 [TBL] [Abstract][Full Text] [Related]
32. Current update on borderline ovarian neoplasms. Lalwani N; Shanbhogue AK; Vikram R; Nagar A; Jagirdar J; Prasad SR AJR Am J Roentgenol; 2010 Feb; 194(2):330-6. PubMed ID: 20093592 [TBL] [Abstract][Full Text] [Related]
33. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908 [TBL] [Abstract][Full Text] [Related]
34. [Role of positron emission tomography in detecting recurrent epithelial ovarian carcinoma]. Zhu X; Shen K; Lang J; Wu M; Huang H; Pan L Zhonghua Fu Chan Ke Za Zhi; 2002 Jun; 37(6):356-8. PubMed ID: 12126572 [TBL] [Abstract][Full Text] [Related]
35. Imaging of cervical lymph nodes in head and neck cancer: the basics. Gor DM; Langer JE; Loevner LA Radiol Clin North Am; 2006 Jan; 44(1):101-10, viii. PubMed ID: 16297684 [TBL] [Abstract][Full Text] [Related]
36. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010 [TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors in advanced ovarian cancer patients]. Terasawa K; Sagae S Nihon Rinsho; 2004 Oct; 62 Suppl 10():592-6. PubMed ID: 15535314 [No Abstract] [Full Text] [Related]
38. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report. Yuan CC; Liu RS; Wang PH; Ng HT; Yeh SH J Reprod Med; 1999 Sep; 44(9):775-8. PubMed ID: 10509300 [TBL] [Abstract][Full Text] [Related]
39. [Ultrasonography and magnetic resonance imaging in diagnosing recurrent and metastatic ovarian cancer]. Bulanova IM; Bulanova TV; Burenchev DV Vestn Rentgenol Radiol; 2006; (1):53-8. PubMed ID: 17195634 [TBL] [Abstract][Full Text] [Related]
40. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]